Citius Oncology Inc. (CTOR)
0.71
0.09 (14.52%)
At close: Mar 24, 2025, 3:58 PM
0.74
4.91%
After-hours: Mar 24, 2025, 05:10 PM EDT
Company Description
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
The company is headquartered in New York, New York.
Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Citius Oncology Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Leonard L. Mazur |
Contact Details
Address: 420 Lexington Avenue New York, New York United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US17331Y1091 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Chairman, Chief Executive Officer & President |
| Jaime Bartushak | Chief Financial Officer & Treasurer |
| Dr. Myron S. Czuczman M.D. | Chief Medical Officer |
| Myron Z. Holubiak | Executive Vice Chairman & Secretary |